The French trial called STIM (Stop Imatinib) - CML - Chronic Myeloid Leukemia
In Stop Imatinib (STIM) study, imatinib treatment (of >2 years duration) was discontinued in patients with CML in CMR (>5-log reduction in BCR-ABL and ABL levels and undetectable transcripts on quantitative RT-PCR).
Important notice: You must inform your CML doctor or a qualified doctor if you want to stop your medication. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.... See our disclamer
VIDEOS
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia
January 10, 2014, OncLive
News from ASCO: Could Some Patients Stop Taking Medication for CML?
February 20, 2013, Patient Power
Is Stopping CML Treatment a Viable Option Now?
January 17, 2013, Patient Power
Can we safely stop TKI therapies? Experience from the STOP trials
Delphine Rea, Hôpital Saint-Louis, Paris, France
December 2012, iCMLf
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia
January 10, 2014, OncLive
News from ASCO: Could Some Patients Stop Taking Medication for CML?
February 20, 2013, Patient Power
Is Stopping CML Treatment a Viable Option Now?
January 17, 2013, Patient Power
Can we safely stop TKI therapies? Experience from the STOP trials
Delphine Rea, Hôpital Saint-Louis, Paris, France
December 2012, iCMLf
ARTICLES
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML
December 15, 2020, National Cancer Institute
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Natural Killer-Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation In Chronic Myeloid Leukemia: The IMMUNOSTIM Study
August 2017, Haemetalogica.org
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
2017, Journal Blood
Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
December 5, 2016, ASH 2016
Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial
December 5, 2016, ASH 2016
TKI Cessation Strategies Emerging for CML
December 4, 2016, OncLive
Cutting Dose, Instead of Stopping Therapy, in Patients With CML
December 5, 2016, Medscape
A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML
December 4, 2016, ASH 2016
Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study
December 3, 2016, ASH 2016
Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs
December 3, 2016, ASH 2016
Long-term Follow-up Confirms Safety of Imatinib Discontinuation in CML
October 5 2016, Cancer Therapy Advisor
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
May 5, 2016, Onco target
Increased Serum Creatinine Reversible Upon Imatinib Discontinuation
March 28, 2016, Cancer Therapy Advisor
Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
2015, Journal Blood
When to Stop Beneficial Treatment in Chronic Myeloid Leukemia
November 25, 2015, CureToday
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
New Criterion for Restarting Therapy in CML
January 8, 2014, Medscape
Predicting the risk of relapse after stopping imatinib in chronic myeloid leukemia
November 19, 2013, Theory, Evolution and Game group
Novartis provides update from treatment-free CML trial
September 23, 2013, Zenopa
Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
September 15, 2013, Cancer Network
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:
results from the TWISTER study
July 25, 2013, Journal Blood
TWIST it but don’t spin it
July 25, 2013, Journal Blood
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
February 26, 2013, PublMed
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
2012, Journal Blood
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
2012, Journal Blood
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML
2012, Journal Blood
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
November 21, 2012, Journal Blood
New Data Confirm Safety of Stopping Imatinib in Leukemia
July 4, 2012, CMLSupport
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
June 2012, Haematologica
Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors (PDF)
May 12, 2012, Molecular Biomarkers & Diagnosis
CML: Stopping TKI Therapy May Be Possible for Some Patients
March 10, 2012, Oncology Times
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML
December 15, 2020, National Cancer Institute
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Natural Killer-Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation In Chronic Myeloid Leukemia: The IMMUNOSTIM Study
August 2017, Haemetalogica.org
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
April 12, 2017, PublMed
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
2017, Journal Blood
Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
December 5, 2016, ASH 2016
Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial
December 5, 2016, ASH 2016
TKI Cessation Strategies Emerging for CML
December 4, 2016, OncLive
Cutting Dose, Instead of Stopping Therapy, in Patients With CML
December 5, 2016, Medscape
A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML
December 4, 2016, ASH 2016
Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study
December 3, 2016, ASH 2016
Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs
December 3, 2016, ASH 2016
Long-term Follow-up Confirms Safety of Imatinib Discontinuation in CML
October 5 2016, Cancer Therapy Advisor
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
May 5, 2016, Onco target
Increased Serum Creatinine Reversible Upon Imatinib Discontinuation
March 28, 2016, Cancer Therapy Advisor
Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
2015, Journal Blood
When to Stop Beneficial Treatment in Chronic Myeloid Leukemia
November 25, 2015, CureToday
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome
2014, American Society of Clinical Oncology
New Criterion for Restarting Therapy in CML
January 8, 2014, Medscape
Predicting the risk of relapse after stopping imatinib in chronic myeloid leukemia
November 19, 2013, Theory, Evolution and Game group
Novartis provides update from treatment-free CML trial
September 23, 2013, Zenopa
Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
September 15, 2013, Cancer Network
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:
results from the TWISTER study
July 25, 2013, Journal Blood
TWIST it but don’t spin it
July 25, 2013, Journal Blood
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
February 26, 2013, PublMed
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
2012, Journal Blood
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
2012, Journal Blood
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML
2012, Journal Blood
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
November 21, 2012, Journal Blood
New Data Confirm Safety of Stopping Imatinib in Leukemia
July 4, 2012, CMLSupport
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
June 2012, Haematologica
Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors (PDF)
May 12, 2012, Molecular Biomarkers & Diagnosis
CML: Stopping TKI Therapy May Be Possible for Some Patients
March 10, 2012, Oncology Times
Presentations - STIM STop IMatinib - Update (FX Mahon)
December 20, 2011, CML Advocates Network
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
December 10, 2011, Hematalogy
Recent advances in the path toward the cure for chronic myeloid leukemia
September 30, 2011, NCBI
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
August 2, 2011, Haematologica
Stopping CML therapies and eradicating CML: Patient perspective from EHA
June 15, 2011, CML Advocates Network
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
December 20, 2011, CML Advocates Network
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
December 10, 2011, Hematalogy
Recent advances in the path toward the cure for chronic myeloid leukemia
September 30, 2011, NCBI
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
August 2, 2011, Haematologica
Stopping CML therapies and eradicating CML: Patient perspective from EHA
June 15, 2011, CML Advocates Network
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
CML Patients Stay in Remission Two Years After Imatinib
October 21, 2010, DoctorsLounge
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, CMLSupport
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
December 8, 2009, Heamatologica
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
2008, Journal Blood
October 21, 2010, DoctorsLounge
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, CMLSupport
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
December 8, 2009, Heamatologica
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
2008, Journal Blood
See also Treatment free remission (TFR)
